Veru (VERU) Restructuring Costs (2016 - 2017)

Veru (VERU) posted quarterly Restructuring Costs of -$73099.0 for Q3 2017, down 198.13% quarter-over-quarter from $74495.0 in Q2 2017.

Veru (VERU) Restructuring Costs (2016 - 2017) Analysis & Trends

Veru (VERU) has reported Restructuring Costs for 2 consecutive years, with -$73099.0 the latest figure, recorded in Q3 2017.

In Q3 2017, Restructuring Costs changed N/A year-over-year to -$73099.0; the TTM figure through Sep 2017 stood at $935781.0 (changed N/A YoY), while the FY2017 annual figure was $935781.0, down 36.88% from the prior year.
Restructuring Costs slipped to -$73099.0 in Q3 2017 per VERU's latest filing, from $74495.0 in the prior quarter.
Across five years, Restructuring Costs topped out at $826370.0 in Q4 2016 and bottomed at -$73099.0 in Q3 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	140.29 Bn	132.43 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.58 Bn	78.58 Bn	3.93 Bn
3	Argenx Se	65.26 Bn	60.08 Bn	1.37 Bn
4	Moderna	61.87 Bn	56.73 Bn	52.00 Mn
5	BeOne Medicines	42.18 Bn	37.08 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.51 Bn	28.20 Bn	992.69 Mn
7	BioNTech SE	28.90 Bn	10.51 Bn	668.28 Mn
8	Insmed	27.46 Bn	26.30 Bn	358.27 Mn
9	Royalty Pharma	27.24 Bn	26.41 Bn	-
10	Veru	61.20 Mn	35.41 Mn	-

Download Data